A Study of Lumigan® in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)
Call us @: 844 663-3742
Study Details
Medical Condition
Study Phase
Intervention Type
Date
Participation Requirements
Gender
Age
Healthy Volunteers
Inclusion Criteria
Exclusion Criteria
Have a question?
You can ask us questions via online form or phone call.
Call us @: 844 663-3742
| Location | Status | Site Contact Details |
|---|---|---|
Location Berlin | Status Not Available |
This is an observational study of Lumigan® 0.01% (bimatoprost) treatment in clinical practice for patients with Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT).
Change From Baseline in Intraocular Pressure (IOP)
Time Frame: Baseline, 14 Weeks
Patient Assessment of Tolerability Using a 4-Point Scale
Time Frame: 14 Weeks
Physician Assessment of Tolerability Using a 4-Point Scale
Time Frame: 14 Weeks
Patients Who Discontinued Use of Lumigan® Prior to 14 Weeks
Time Frame: 14 Weeks
Patients Who Will Continue Use of Lumigan® After 14 Weeks
Time Frame: 14 Weeks
Interventions:
- Drug: bimatoprost 0.01%
Enrollment:
10337
Additional Information
Watch a video to learn more about what you may experience as a clinical trial volunteer: /resources/what-happens-in-a-clinical-trial
Take a virtual reality screening visit tour to an example of a clinical trial site: /resources/screening-visit-virtual-tour
Use a questionnaire tool to think through questions to ask yourself about participating in a clinical trial and print out your responses to discuss with your partners in your health journey: /resource-information-clinical-trial-community/decision-counselor